Biotech Week Boston 2017 in Photos

If you were among the few that missed Biotech Week Boston 2017 then you missed a lot. The event, in its second year, was jam packed with insightful sessions, rooms filled with scientists, pharma innovators, sponsors and exhibitors.

We’ve gathered some of the best photos from BWB to recap the four-day event that ran September 25th through September 28th, 2017.


The keynote speakers, J Craig Venter, Flemming Ornskov, James J. Collins, Dean K. Pettit and Tyler Jacks took to the main stage to share insightful data and new developments in bioprocessing and cell and gene therapy.

Continue reading “Biotech Week Boston 2017 in Photos”

Manufacturing Strategies and Solutions for Gene Therapies

By: Stephen Moore

The Manufacturing Strategies and Solutions for Gene Therapies session was introduced by Lisa Bradbury PhD, Director of Research & Development of the Proteomics & Cell Therapy Programs at Pall Life Sciences. She briefly spoke of the challenges and innovation that are required in the production of gene therapeutics. She stated that lessons can be taken from the scale-up of antibody production, but reminded the audience that many of the issues with the scaling-up of gene therapies are unique.

Achieving Large-Scale GMP Production of Adenovirus in the iCELLis 500 Fixed-Bed Bioreactor.

The first presentation of the session was given by Dr Hannah Lesch, the Research & Development Director at FinVector Vision Therapies. FinVector Vision Therapies is a Biotechnology company based in Finland that specializes in the research and development of Viral-Based Gene Therapy Products. Dr Lesch started by introducing the layout of their laboratory and production facilities. She then spoke on the steps that they undertook when scaling-up the production of one of their drug candidates, a adenoviral gene therapy vector encoding the gene IFNa2b, which is being tested for use in the treatment of refactory non-muscle invasive bladder cancer. After FinVector Vision Therapies had shown that they could generate the transfected vector, they decided to scale-up production. To do this they turned to the iCELLis bioreactor system produced by Pall Corporation. The iCELLis bioreactor is a single use fixed-bed reactor that is available in two formats, the iCELLis nano and the iCELLis 500. They found for the most part the scale-up was relatively straightforward. Dr Lesch reported that the main issue they found was when it came replacement of media in the bioreactors. She also reported that cell distribution in the fixed-bed bioreactor was relatively even, scalability was good, productivity was improved, and that there was process consistency across the four batches they had produced so far.

Continue reading “Manufacturing Strategies and Solutions for Gene Therapies”